Study drug for HPV18-positive solid tumors with a specific immune marker
Treatments studied
Part of Cancer, Digestive system, Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 1 trial tests HRYZ-T101 injection for people whose solid cancer is HPV18-positive and who have the HLA-DRB1*0901 immune marker. It is meant for people whose cancer has returned or spread and who have few or no effective treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old and willing to sign informed consent.
- Your cancer is metastatic or recurrent solid tumor confirmed to be HPV18-positive.
- Your blood test must show the HLA-DRB1*0901 immune marker is present.
- Your overall health should be good enough for study treatment (ECOG score 0–1) and you’re expected to live at least 3 months.
- You must have at least one measurable cancer area on scans, and your blood/organ tests must meet minimum levels.
- If you can become pregnant, you must use effective birth control during the study and for at least 1 year after cell treatment (pregnancy test must be negative).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug, TI-0093, for people with HPV‑16 positive solid tumors (like head and neck or cervical cancer) that have come back or spread after standard treatments. The goal is to see if the drug can help shrink tumors or slow their growth.
This Phase 1/2 trial tests a one-time infusion of special immune T cells made to recognize your HPV16 tumor. It may help your body attack the cancer, while researchers closely monitor safety and early effectiveness.
This Phase 2 trial tests an immune-cell treatment (E7 TCR T cells) designed to attack cancers caused by HPV type 16. It may help people whose HPV-16+ cancer has come back or not responded to standard treatment.
This early-phase study tests a lab-made treatment using your own immune cells (T cells) to target HPV-related throat cancers. It aims to reduce cancer by directing your immune system against HPV16/HPV18 and a protein called survivin.
This trial tests an experimental cell treatment called HRYZ-T102 TCR-T for people with advanced liver cancer or other solid tumors that make a protein called AFP. The treatment uses your own immune cells, modified in a lab to target and kill cancer cells.
This Phase 1 trial tests HS-10386 (an experimental treatment) in people with advanced solid tumors that can’t be cured with standard options. The goal is to find a safe dose and see how the cancer responds.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.